0001209191-22-041053.txt : 20220706 0001209191-22-041053.hdr.sgml : 20220706 20220706160456 ACCESSION NUMBER: 0001209191-22-041053 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220705 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Plavsic Mark CENTRAL INDEX KEY: 0001868719 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 221068662 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 651311552 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-05 0 0001434316 FATE THERAPEUTICS INC FATE 0001868719 Plavsic Mark C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 0 1 0 0 Chief Technical Officer Common Stock 2022-07-05 4 S 0 3719 24.61 D 127123 D Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 9,500 shares of Common Stock underlying restricted stock units granted to the Reporting Person on June 14, 2021. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Represents the weighted average sale price of the shares sold from $24.34 to $24.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2. /s/ Cindy Tahl, as Attorney-in-Fact 2022-07-06